Brief: Genmab Says Phase 1/2 Rainfol-01 Data Show Rina-S And Bevacizumab Combination Tolerable
April 13 (Reuters) - Genmab A/S GMAB.CO: REG-GENMAB PRESENTS THE SAFETY AND TOLERABILITY OF RINATABART SESUTECAN (RINA-S®) IN COMBINATION WITH BEVACIZUMAB IN ADVANCED OVARIAN CANCER PHASE 1/2 RAINFOL-01 DATA SHOW RINA-S AND BEVACIZUMAB COMBINATION TOLERABLE WITH NO NEW SAFETY SIGNALS Source text: ID:nGNE9q3Z7q Further company coverage: GMAB.CO (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 772 0920;))
Recent news on Genmab A/S
See all newsBrief: Genmab Says Orbis Investment Management Holds 4.99% Of Genmab Voting Rights As Of June 12
Brief: Genmab Announces Epcoritamab Monotherapy And Epcoritamab-Based Combination Regimens Demonstrate High Response Rates In Elderly Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma
Brief: Genmab Presents Epcore Fl-1 Data Showing Consistent Efficacy, Safety For Epcoritamab Combination
Brief: Genmab Says Orbis Investment Management Limited Holds 5.08% Of Genmab A/S As Of May 8, 2026
Genmab falls after 'uneventful' Q1, profit miss